Monogram Technologies and Zimmer Biomet Extend Antitrust Review Period for Merger, Expected to Complete in Late 2025
Monogram Technologies Inc. has provided an update on its pending merger with Zimmer Biomet Holdings, Inc. The company announced that Zimmer Biomet, in agreement with Monogram, voluntarily withdrew and subsequently resubmitted its pre-merger Notification and Report Form to allow the Federal Trade Commission additional time for review. This move is part of the ongoing cooperation with regulatory authorities to facilitate the merger process. The new 30-day waiting period began on September 4, 2025, and is expected to conclude on October 6, 2025. Monogram and Zimmer Biomet remain committed to completing the merger in the second half of 2025, contingent on receiving necessary regulatory approvals and fulfilling other standard conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monogram Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-087631), on September 05, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。